Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.60 |
| ▸ | CTSK | P43235 | 9/20 | 0.57 |
| ▸ | CTSL | P07711 | 8/20 | 0.54 |
| ▸ | CTSS | P25774 | 3/20 | 0.54 |
| ▸ | CTSB | P07858 | 5/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27001675 | 1.00 | CAPN1 (0.60) | CAPN1CTSKCTSLCTSSCTSB | |
| SCHEMBL27406798 | 0.94 | CAPN1 (0.58) | CAPN1CTSKCTSLCTSSCTSB | |
| SCHEMBL28806164 | 0.92 | ITGB3 (0.53) | CTSKCTSLCTSSCTSB | |
| SCHEMBL28806163 | 0.92 | ITGB3 (0.53) | CTSKCTSLCTSSCTSB | |
| SCHEMBL17685892 | 0.90 | ITGB3 (0.56) | CTSLCTSSCTSB | |
| SCHEMBL29838907 | 0.90 | ITGB3 (0.56) | CTSLCTSSCTSB | |
| SCHEMBL2928061 | 0.86 | CAPN1 (0.67) | CAPN1CTSKCTSLCTSSCTSB | |
| SCHEMBL25471796 | 0.86 | TYR (0.54) | CTSKCTSLCTSSCTSB | |
| SCHEMBL29774427 | 0.86 | TYR (0.54) | CTSKCTSLCTSSCTSB | |
| SCHEMBL14148469 | 0.86 | CAPN1 (0.72) | CAPN1CTSKCTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207410-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2024-06-27 | — | — | US | disclosed |
| EP-4305049-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | Neuroderm Ltd (IL) | 2024-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207410-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | COMT, TH, DDT | CAPN1 3542/4885CTSK 1464/4885CTSL 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.